Skip to main content
NCBI home page
British Journal of Cancer logoLink to British Journal of Cancer
. 2001 Aug;85(3):393–397. doi: 10.1054/bjoc.2001.1883

Expression and regulation of prostate androgen regulated transcript-1 (PART-1) and identification of differential expression in prostatic cancer

M Sidiropoulos 1, A Chang 1,2, K Jung 3, E P Diamandis 1,2
PMCID: PMC2364080  PMID: 11487271

Abstract

Prostate androgen regulated transcript 1 (PART-1), is a gene predominantly expressed in the prostate gland and is regulated by androgens in human prostate cancer cell lines. Here, we report additional characteristics of PART-1 tissue expression and hormonal regulation and study its expression profile in human normal and matched prostate cancer tissues. Since PART-1 shows similarity to prostate-specific antigen (PSA) in prostate specificity and regulation, we hypothesized that it may be implicated in prostate carcinogenesis or may be a potential new biomarker. We used reverse transcriptase polymerase chain reaction (RT-PCR) to further characterize PART-1 tissue expression and hormonal regulation in the LNCaP prostate cancer cell line. RT-PCR analysis revealed that PART-1 is expressed not only in the prostate and salivary gland, but also in other tissues, including the thymus and placenta. In addition to androgen stimulation, PART-1 is also up-regulated by progestins, oestrogens and glucocorticoids. We further studied the expression of PART-1 in 27 paired (from the same patient) cancerous and non-cancerous prostatic tissues, with qualitative and quantitative RT-PCR (LightCycler®technology), in order to examine whether PART-1 is overexpressed or underexpressed in cancer. Our results indicated that PART-1 is more frequently overexpressed in the cancerous prostatic tissue. We conclude that this gene is overexpressed in prostate cancer and may represent a novel prostate cancer tumour marker. © 2001 Cancer Research Campaign http://www.bjcancer.com

Keywords: prostate cancer, androgen regulated transcript, quantitative RT-PCR, differentially expressed genes, tumour markers, PART-1

Full Text

The Full Text of this article is available as a PDF (95.8 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Black M. H., Diamandis E. P. The diagnostic and prognostic utility of prostate-specific antigen for diseases of the breast. Breast Cancer Res Treat. 2000 Jan;59(1):1–14. doi: 10.1023/a:1006380306781. [DOI] [PubMed] [Google Scholar]
  2. Diamandis E. P. Prostate-specific antigen: a cancer fighter and a valuable messenger? Clin Chem. 2000 Jul;46(7):896–900. [PubMed] [Google Scholar]
  3. Haese A., Becker C., Noldus J., Graefen M., Huland E., Huland H., Lilja H. Human glandular kallikrein 2: a potential serum marker for predicting the organ confined versus non-organ confined growth of prostate cancer. J Urol. 2000 May;163(5):1491–1497. doi: 10.1016/s0022-5347(05)67649-5. [DOI] [PubMed] [Google Scholar]
  4. Lin B., White J. T., Ferguson C., Bumgarner R., Friedman C., Trask B., Ellis W., Lange P., Hood L., Nelson P. S. PART-1: a novel human prostate-specific, androgen-regulated gene that maps to chromosome 5q12. Cancer Res. 2000 Feb 15;60(4):858–863. [PubMed] [Google Scholar]
  5. Magklara A., Scorilas A., Catalona W. J., Diamandis E. P. The combination of human glandular kallikrein and free prostate-specific antigen (PSA) enhances discrimination between prostate cancer and benign prostatic hyperplasia in patients with moderately increased total PSA. Clin Chem. 1999 Nov;45(11):1960–1966. [PubMed] [Google Scholar]
  6. Magklara A., Scorilas A., Stephan C., Kristiansen G. O., Hauptmann S., Jung K., Diamandis E. P. Decreased concentrations of prostate-specific antigen and human glandular kallikrein 2 in malignant versus nonmalignant prostatic tissue. Urology. 2000 Sep 1;56(3):527–532. doi: 10.1016/s0090-4295(00)00621-x. [DOI] [PubMed] [Google Scholar]
  7. McCormack R. T., Rittenhouse H. G., Finlay J. A., Sokoloff R. L., Wang T. J., Wolfert R. L., Lilja H., Oesterling J. E. Molecular forms of prostate-specific antigen and the human kallikrein gene family: a new era. Urology. 1995 May;45(5):729–744. doi: 10.1016/s0090-4295(99)80076-4. [DOI] [PubMed] [Google Scholar]
  8. McDavid K., Melnik T. A., Derderian H. Prostate cancer screening trends of New York State men at least 50 years of age, 1994 to 1997. Prev Med. 2000 Sep;31(3):195–202. doi: 10.1006/pmed.2000.0709. [DOI] [PubMed] [Google Scholar]
  9. McDonald S., Brive L., Agus D. B., Scher H. I., Ely K. R. Ligand responsiveness in human prostate cancer: structural analysis of mutant androgen receptors from LNCaP and CWR22 tumors. Cancer Res. 2000 May 1;60(9):2317–2322. [PubMed] [Google Scholar]
  10. Moran W. P., Cohen S. J., Preisser J. S., Wofford J. L., Shelton B. J., McClatchey M. W. Factors influencing use of the prostate-specific antigen screening test in primary care. Am J Manag Care. 2000 Mar;6(3):315–324. [PubMed] [Google Scholar]
  11. Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
  12. Rhim J. S. Molecular and genetic mechanisms of prostate cancer. Radiat Res. 2001 Jan;155(1 Pt 2):128–132. doi: 10.1667/0033-7587(2001)155[0128:magmop]2.0.co;2. [DOI] [PubMed] [Google Scholar]
  13. Rittenhouse H. G., Finlay J. A., Mikolajczyk S. D., Partin A. W. Human Kallikrein 2 (hK2) and prostate-specific antigen (PSA): two closely related, but distinct, kallikreins in the prostate. Crit Rev Clin Lab Sci. 1998 Aug;35(4):275–368. doi: 10.1080/10408369891234219. [DOI] [PubMed] [Google Scholar]
  14. Veldscholte J., Berrevoets C. A., Ris-Stalpers C., Kuiper G. G., Jenster G., Trapman J., Brinkmann A. O., Mulder E. The androgen receptor in LNCaP cells contains a mutation in the ligand binding domain which affects steroid binding characteristics and response to antiandrogens. J Steroid Biochem Mol Biol. 1992 Mar;41(3-8):665–669. doi: 10.1016/0960-0760(92)90401-4. [DOI] [PubMed] [Google Scholar]
  15. Webb V., Holmes A. Urological cancers: do early detection strategies exist? BJU Int. 2000 Dec;86(9):996–1000. doi: 10.1046/j.1464-410x.2000.00971.x. [DOI] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES